The Impact of Race in Male Breast Cancer Treatment and Outcome in the United States: A Population-Based Analysis of 4,279 Patients

The purpose of this study is to compare the racial differences in treatment and overall survival (OS) of male breast cancer (MBC) patients. Data were extracted from the NCI SEER database that included population-based registries from 1988 to 2010 and analyzed using SPSS 20.0. 4,279 MBC patients were...

Full description

Saved in:
Bibliographic Details
Main Authors: Jacob Y. Shin, Lisa A. Kachnic, Ariel E. Hirsch
Format: Article
Language:English
Published: Wiley 2014-01-01
Series:International Journal of Breast Cancer
Online Access:http://dx.doi.org/10.1155/2014/685842
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832566896448241664
author Jacob Y. Shin
Lisa A. Kachnic
Ariel E. Hirsch
author_facet Jacob Y. Shin
Lisa A. Kachnic
Ariel E. Hirsch
author_sort Jacob Y. Shin
collection DOAJ
description The purpose of this study is to compare the racial differences in treatment and overall survival (OS) of male breast cancer (MBC) patients. Data were extracted from the NCI SEER database that included population-based registries from 1988 to 2010 and analyzed using SPSS 20.0. 4,279 MBC patients were identified. 3,266 (76.3%) patients were White, 552 (12.9%) Black, 246 (5.7%) Hispanic, and 215 (5.0%) Asian. Black patients were more likely to be diagnosed at younger age (P<0.001), have advanced stage disease (P=0.001), and be unmarried (P<0.001) and less likely to undergo lymph node dissection (P=0.006). When stratified by stage, there was no difference in receipt of primary treatment by race. The 5-year OS for White, Black, Hispanic, and Asian races was 73.8%, 66.3%, 74.0%, and 85.3% (P<0.001). This significant worse 5-year OS for Blacks persisted regardless of age, stage II or III disease, and grade 2 or 3 disease. On multivariate analysis, Black race was a significant independent prognostic factor for worse OS. Blacks were less likely to receive lymph node dissection of which patients may derive benefit, though we did not observe receipt of primary treatment, after stratifying for disease stage, to be an underlying factor contributing to racial outcome differences.
format Article
id doaj-art-5be075cb21414ad39c64cf9416a68270
institution Kabale University
issn 2090-3170
2090-3189
language English
publishDate 2014-01-01
publisher Wiley
record_format Article
series International Journal of Breast Cancer
spelling doaj-art-5be075cb21414ad39c64cf9416a682702025-02-03T01:02:52ZengWileyInternational Journal of Breast Cancer2090-31702090-31892014-01-01201410.1155/2014/685842685842The Impact of Race in Male Breast Cancer Treatment and Outcome in the United States: A Population-Based Analysis of 4,279 PatientsJacob Y. Shin0Lisa A. Kachnic1Ariel E. Hirsch2Department of Radiation Oncology, Boston Medical Center and Boston University School of Medicine, 830 Harrison Avenue, Moakley Building LL 100, Boston, MA 02118, USADepartment of Radiation Oncology, Boston Medical Center and Boston University School of Medicine, 830 Harrison Avenue, Moakley Building LL 100, Boston, MA 02118, USADepartment of Radiation Oncology, Boston Medical Center and Boston University School of Medicine, 830 Harrison Avenue, Moakley Building LL 100, Boston, MA 02118, USAThe purpose of this study is to compare the racial differences in treatment and overall survival (OS) of male breast cancer (MBC) patients. Data were extracted from the NCI SEER database that included population-based registries from 1988 to 2010 and analyzed using SPSS 20.0. 4,279 MBC patients were identified. 3,266 (76.3%) patients were White, 552 (12.9%) Black, 246 (5.7%) Hispanic, and 215 (5.0%) Asian. Black patients were more likely to be diagnosed at younger age (P<0.001), have advanced stage disease (P=0.001), and be unmarried (P<0.001) and less likely to undergo lymph node dissection (P=0.006). When stratified by stage, there was no difference in receipt of primary treatment by race. The 5-year OS for White, Black, Hispanic, and Asian races was 73.8%, 66.3%, 74.0%, and 85.3% (P<0.001). This significant worse 5-year OS for Blacks persisted regardless of age, stage II or III disease, and grade 2 or 3 disease. On multivariate analysis, Black race was a significant independent prognostic factor for worse OS. Blacks were less likely to receive lymph node dissection of which patients may derive benefit, though we did not observe receipt of primary treatment, after stratifying for disease stage, to be an underlying factor contributing to racial outcome differences.http://dx.doi.org/10.1155/2014/685842
spellingShingle Jacob Y. Shin
Lisa A. Kachnic
Ariel E. Hirsch
The Impact of Race in Male Breast Cancer Treatment and Outcome in the United States: A Population-Based Analysis of 4,279 Patients
International Journal of Breast Cancer
title The Impact of Race in Male Breast Cancer Treatment and Outcome in the United States: A Population-Based Analysis of 4,279 Patients
title_full The Impact of Race in Male Breast Cancer Treatment and Outcome in the United States: A Population-Based Analysis of 4,279 Patients
title_fullStr The Impact of Race in Male Breast Cancer Treatment and Outcome in the United States: A Population-Based Analysis of 4,279 Patients
title_full_unstemmed The Impact of Race in Male Breast Cancer Treatment and Outcome in the United States: A Population-Based Analysis of 4,279 Patients
title_short The Impact of Race in Male Breast Cancer Treatment and Outcome in the United States: A Population-Based Analysis of 4,279 Patients
title_sort impact of race in male breast cancer treatment and outcome in the united states a population based analysis of 4 279 patients
url http://dx.doi.org/10.1155/2014/685842
work_keys_str_mv AT jacobyshin theimpactofraceinmalebreastcancertreatmentandoutcomeintheunitedstatesapopulationbasedanalysisof4279patients
AT lisaakachnic theimpactofraceinmalebreastcancertreatmentandoutcomeintheunitedstatesapopulationbasedanalysisof4279patients
AT arielehirsch theimpactofraceinmalebreastcancertreatmentandoutcomeintheunitedstatesapopulationbasedanalysisof4279patients
AT jacobyshin impactofraceinmalebreastcancertreatmentandoutcomeintheunitedstatesapopulationbasedanalysisof4279patients
AT lisaakachnic impactofraceinmalebreastcancertreatmentandoutcomeintheunitedstatesapopulationbasedanalysisof4279patients
AT arielehirsch impactofraceinmalebreastcancertreatmentandoutcomeintheunitedstatesapopulationbasedanalysisof4279patients